DrugPatentWatch Database Preview
Foldrx Pharms Company Profile
Email this page to a colleague
See Plans and PricingWhat is the competitive landscape for FOLDRX PHARMS, and when can generic versions of FOLDRX PHARMS drugs launch?
FOLDRX PHARMS has two approved drugs.
There are five US patents protecting FOLDRX PHARMS drugs.
There are forty-seven patent family members on FOLDRX PHARMS drugs in twenty-three countries and thirteen supplementary protection certificates in twelve countries.
Summary for Foldrx Pharms
| International Patents: | 47 |
| US Patents: | 5 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Foldrx Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | 7,214,696 | Start Trial | Start Trial | ||||
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Foldrx Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2373639 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2016038500 | Start Trial |
| South Korea | 20050090410 | Start Trial |
| Russian Federation | 2017107235 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Foldrx Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1587821 | 126 5003-2012 | Slovakia | Start Trial | PRODUCT NAME: TAFAMIDIS MEGLUMIN; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | 1290005-6 | Sweden | Start Trial | PERIOD OF VALIDITY AFTER CORRECTION (FROM - UNTIL): 20231220 - 20261117 |
| 1587821 | CA 2012 00006 | Denmark | Start Trial | |
| 1587821 | C 2012 004 | Romania | Start Trial | PRODUCT NAME: TAFAMIDISMEGLUMINA; NATIONAL AUTHORISATION NUMBER: EU/1/11/717/001; DATE OF NATIONAL AUTHORISATION: 20111116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/717/001; DATE OF FIRST AUTHORISATION IN EEA: 20111116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
